Innovative Bladder Cancer Therapy Reprograms Bone Marrow to Enhance Immune Response
New research uncovers how bladder cancer treatment with BCG reprograms the bone marrow to enhance the body's innate immune response, improving cancer-fighting capabilities.
A groundbreaking study by researchers at Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center (MSK) reveals that bladder cancer treatment with Bacillus Calmette-Guérin (BCG) not only stimulates a local immune response but also induces systemic immunological changes by reprogramming the bone marrow. BCG, a weakened form of Mycobacterium bovis, has long been used as a frontline immunotherapy for early-stage bladder cancer. Traditionally thought to act mainly at the tumor site by enhancing T cell activity, new evidence suggests that BCG's effects extend deeper into the body's immune system.
The research demonstrates that BCG travels from the bladder to the bone marrow, influencing the production of immune cells called myeloid cells. This process primes the innate immune system, enabling it to respond more effectively to cancer cells and other threats. Using advanced analytical techniques like Progenitor Input Enrichment sequencing (PIE-seq), scientists studied gene activity in blood samples from bladder cancer patients treated with BCG, discovering significant changes in stem cell programming in the bone marrow.
Notably, the study shows that the reprogrammed stem cells generate more potent immune cells capable of attacking tumors. Additionally, combining BCG with checkpoint inhibitors—a type of immunotherapy that boosts T cell activity—resulted in more effective tumor suppression and increased survival in mouse models. This synergy indicates potential for enhancing current cancer treatments by harnessing innate immunity.
The findings broaden the understanding of BCG's anti-cancer mechanisms, highlighting its capacity to shape systemic immune responses beyond the bladder. The research also opens pathways for developing strategies that stimulate immune cell reprogramming to improve immunotherapy outcomes across various cancer types.
This work underscores the importance of innate immune system training in cancer therapy and suggests that leveraging bone marrow reprogramming could augment existing immunotherapies, paving the way for more effective treatment protocols.
Source: https://medicalxpress.com/news/2025-05-bladder-cancer-treatment-reprograms-bone.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Empowering Back Pain Patients: The Importance of Choices and Facts
New research emphasizes the importance of providing evidence-based, balanced information to people with back pain, promoting shared decision-making over advice-based guidance.
Two Butcher Shops in Northern France Shut Down Following Child Death Due to Food Poisoning
Two butcher shops in Saint-Quentin, France, have closed following a child's death from food poisoning caused by contaminated meat. An ongoing investigation aims to identify the source of infection and prevent further cases.
Shorter Treatment Regimen Shows Promise for Some Patients with Drug-Resistant Tuberculosis
A groundbreaking study reveals that a shorter, targeted treatment regimen can be effective for some patients with pre-extensively drug-resistant tuberculosis, paving the way for more personalized therapies.
Key Differences in STING Inhibition Between Humans and Mice Uncovered by Researchers
A groundbreaking study uncovers key differences in the STING pathway between humans and mice, influencing future drug development for immune-related therapies. Read about how these discoveries could shape treatments for cancer, neurodegeneration, and autoimmune diseases.